Allergy Therapeutics plc’s (AGY) “Buy” Rating Reaffirmed at Panmure Gordon
Panmure Gordon restated their buy rating on shares of Allergy Therapeutics plc (LON:AGY) in a research report report published on Monday morning. The firm currently has a GBX 53 ($0.66) target price on the stock.
A number of other research firms have also issued reports on AGY. Numis Securities Ltd reiterated a buy rating and issued a GBX 37 ($0.46) target price on shares of Allergy Therapeutics plc in a report on Tuesday, September 27th. Stifel Nicolaus restated a buy rating and issued a GBX 72 ($0.89) price target on shares of Allergy Therapeutics plc in a research note on Friday, July 8th.
Shares of Allergy Therapeutics plc (LON:AGY) opened at 20.60 on Monday. The stock’s market cap is GBX 121.37 million. Allergy Therapeutics plc has a 52 week low of GBX 17.25 and a 52 week high of GBX 34.82. The stock has a 50 day moving average price of GBX 18.88 and a 200-day moving average price of GBX 22.06.
In other Allergy Therapeutics plc news, insider Peter Jensen purchased 30,000 shares of the business’s stock in a transaction on Thursday, September 29th. The shares were bought at an average cost of GBX 19 ($0.24) per share, for a total transaction of £5,700 ($7,054.46). Also, insider Nicolas Wykeman purchased 150,000 shares of the business’s stock in a transaction on Tuesday, September 27th. The stock was acquired at an average price of GBX 18 ($0.22) per share, for a total transaction of £27,000 ($33,415.84).
About Allergy Therapeutics plc
Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.